信立泰前三季度净利5.81亿元，同比增长13.93%

Core Insights - The company reported a revenue of 3.241 billion yuan for the first three quarters of 2025, representing an 8% year-on-year growth [1] - The net profit attributable to shareholders reached 581 million yuan, showing a year-on-year increase of 13.93% [1] Sales Structure - The revenue growth of new products has accelerated, becoming the core driver of the company's development [1] - The company is focusing on the chronic disease field of CKM (cardiovascular and metabolic syndrome) [1] Product Pipeline - The company has continuously enriched its innovative product pipeline [1] - Newly launched products, Xinchao Tuo and Fuli An, have passed the national medical insurance negotiation review, and the company is actively preparing for related negotiations [1]